Eagle Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Graves
- Full Time Employees
- 134
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 50 Tice Boulevard Woodcliff Lake NJ United States of America 07677
- IPO Date
- Feb 12, 2014
- CIK
- 0000827871
- Website
- eagleus.com
- Similar Companies
- Business
- Eagle Pharmaceuticals, Inc. (EGRX) develops, manufactures and commercializes injectable products for niche hospital markets, including critical care, oncology, and anesthesia; its portfolio features branded and generic formulations such as vasopressin injection, PEMFEXY (pemetrexed for injection), BYFAVO (remimazolam for injection), RYANODEX (dantrolene sodium), and BARHEMSYS (amisulpride injection), alongside a pipeline of product candidates leveraging proprietary delivery technologies like Bendeka and Belrapzo. The company operates primarily in the United States, with headquarters in Woodcliff Lake, New Jersey, where it was founded in 2007 as a specialty pharmaceutical provider targeting hospitals, ambulatory surgery centers, and oncology clinics. Eagle Pharmaceuticals maintains a focused business model in the biopharmaceutical sector, emphasizing hospital-administered therapies with limited generic competition. In recent developments, Eagle Pharmaceuticals completed the acquisition of Acacia Pharma Group plc in 2021, expanding its portfolio with BYFAVO and BARHEMSYS for procedural sedation and postoperative nausea; it launched PEMFEXY in 2022 as a ready-to-use oncology treatment and gained FDA approval for expanded indications on select products through 2024. The company reported strategic partnerships for distribution and co-promotion in critical care segments during 2024, alongside funding from product sales growth amid ongoing pipeline advancements in emergency medicine injectables. No major name changes, reorganizations, or new funding rounds were announced in 2025.
Critical Contrast: Eagle Pharmaceuticals (NASDAQ:EGRX) & Indivior (OTCMKTS:INVVY)
Did Eagle Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Pass Above 50-Day Moving Average – Should You Sell?
Eagle Pharmaceuticals Announces Divestiture of Barhemsys
Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Pass Below Fifty Day Moving Average – Here’s What Happened
Aadi Bioscience (NASDAQ:AADI) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Survey
HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Passes Below 200 Day Moving Average – What’s Next?
Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
Eagle Pharmaceuticals Announces 2025 Annual Meeting Date
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders
Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida